Immix Biopharma Presents NXC-201 Data At 65th American Society Of Hematology Annual Meeting In 9 Relapsed/Refractory AL Amyloidosis Patients
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma presented data on NXC-201 at the 65th American Society of Hematology Annual Meeting, showing a 100% overall response rate in 9 relapsed/refractory AL Amyloidosis patients who had undergone a median of 6 lines of prior therapy. Updated results will be communicated on December 10, 2023.
November 06, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's NXC-201 showed a 100% response rate in AL Amyloidosis patients, which could potentially boost the company's reputation and stock value.
The 100% response rate of NXC-201 in AL Amyloidosis patients is a significant positive development for Immix Biopharma. This could potentially lead to increased investor confidence and a rise in the company's stock value, especially if the updated results, to be communicated on December 10, 2023, confirm these initial findings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100